Market Overview

Global Vaccine Adjuvants Market size accrued earnings worth approximately USD 12.88 Billion in 2023 and is predicted to gain revenue of about USD 40.58 Billion by 2032 is set to record a CAGR of nearly 13.6% over the period from 2024 to 2032.

The market was influenced immensely by the COVID-19 pandemic. Appropriately added adjuvants to COVID-19 vaccines resulted in highly diminished numbers of the required dose as well as improving efficacy or cross-neutralizing protection. For example, an article on Viruses published in February 2022 reported that despite the successful launch of several vaccines to combat COVID-19, declined protection against specific VOCs was observed in respect of SARS-CoV-2, including breakthrough infections with certain VOCs even in the vaccines. This demanded the increased development of Immunostimulatory Adjuvants that provoke robust and long-lasting protective immunity against SARS-CoV-2 and its variants. Hence, COVID-19 had a positive impact on the Vaccine Adjuvants Market. According to the above reference, adjuvants employed with SARS-CoV-2 vaccine candidates included Aluminium Based Vaccine Adjuvants, STING agonist-based adjuvants, oil-in-water emulsion adjuvants, TLR agonist adjuvants, and many more. Due to the advantage and development of new Vaccine Adjuvants, the demand also increased during the COVID-19 pandemic and is expected to grow in the coming period. The factors that enhance the growth of the Adjuvant Market include unmet demand for specific vaccines, increasing government vaccination recommendations, and increasing use of recombinant subunit and synthetic vaccines. For example, according to the information published by WHO in the Global Tuberculosis Report 2021, most cases of tuberculosis were found in the WHO regions of Southeast Asia (43%), Africa (25%), and Western Pacific (18%), while smaller numbers of tuberculosis cases were found in Eastern Mediterranean (8.3%), the Americas (3.0%), and Europe (2.3%). Additionally, according to the WHO data published in 2021, Sub-Saharan Africa probably continues to bear the burden of malaria, accounting for about 95% of all cases and 96% of all deaths. Thus, increasing cases of infectious diseases are likely to increase the demand for vaccines, and hence the Vaccine Adjuvant Market is going to grow at a very high rate. In addition to that, as per the CDC update in January 2021, to prevent occupational exposure to the Ebola virus species Zaire Ebolavirus, the Advisory Committee on Immunization Practices (ACIP) recommends preexposure vaccination with Ervebo for adults in the U.S. population older than 18 years of age who are at more risk. This is because they are responding to the Ebola virus disease outbreak (EVD). Therefore, increasing government vaccination recommendations is expected to drive market growth. Vaccine Adjuvant Manufacturers are introducing new, more sophisticated Vaccine Adjuvants, which are anticipated to significantly support the market's growth. For instance, in December 2022, Evonik launched PhytoSquene, a non-animal-derived squalling suitable for vaccines and other pharmaceutical applications. PhytoSquene is squalling produced from amaranth oil commercially available for adjuvants in parenteral dosage forms, which satisfies the need for a safe commercial source of non-animal-derived squalling. Such instances are expected to drive the growth of the Vaccine Adjuvant Market over the forecast period. Thus, these factors mentioned above, such as unmet demand for specific vaccines, increasing government vaccination recommendations, and increasing use of recombinant subunit and synthetic vaccines, are anticipated to boost the market's growth over the forecast period. However, this market will face constraints from side effects, the high toxicity of adjuvants, and a high R&D cost to discover a novel adjuvant.

Market Drivers

Rising Prevalence of Infectious Diseases

The increasing prevalence of infectious diseases including influenza, HIV, and most recently COVID-19 has had a tremendous increase in the demand for effective vaccines against these diseases. These diseases form a significant burden to public health with high transmission rates as well as important morbidity and mortality. A vaccine is a valuable tool in curbing outbreaks. However, this efficacy often goes hand in hand with the added substances to these vaccines known as adjuvants.

An adjuvant significantly enhances the vaccines' potency and durability, inducing stronger and prolonged immunity. That is particularly needed for infections as HIV, that requires strong immunization, and in pandemics like COVID19, where, on a larger scale, massive immunization becomes necessary. Emerging new virus types have also challenged the need to develop novel technologies of adjuvants capable of providing more effective vaccines over evolving pathogens. Consequently, the prevalence of infectious diseases has become one of the factors with the highest growth potentials in the market for vaccine adjuvants.

Market Opportunities

Development of Personalized Vaccines

Precision medicine is the adaptation of healthcare, including vaccines, to the specific needs of a patient, in terms of his or her genetic profile, environment, and lifestyle. This paved the way for the development of customized vaccines designed to meet the needs of specific populations, including those with particular immune profiles or pre-existing conditions.

This paradigm would critically depend on adjuvants to enhance the efficacy of such precision vaccines. Adjuvants could be targeted to immunize the individual to a specific age group, such as infants or the elderly, or in the case of patients with weakened immunity. Adjuvant technology, such as nanoparticles and liposomes, has advanced to a degree where it can deliver agents precisely and control immune responses, consistent with the goals of precision medicine. With the increased needs for personalized vaccines, innovative formulations of adjuvants represent great opportunities within the vaccine adjuvants market, differing according to their application with several vaccine platforms. These include, for example, mRNA and DNA vaccines.

Market Restraining Factors

Adverse Effects and Public Perception

Adjuvants are a critical component in vaccines to improve immune responses. However, use of adjuvants often comes with a fear of side effects. Adverse reactions such as autoimmune response or hypersensitivity are seen when the immune system becomes over activated or targets the body wrongly. Though such reactions are very rare, it scares the minds of healthcare providers, regulatory bodies, and the public.

Autoimmune reactions in which the immune system mistakenly attacks the body's tissues are especially concerning in vaccines that contain potent adjuvants designed to elicit high levels of immunity. Hypersensitivity reactions also include mild redness or severe allergic responses, which are a disincentive to accept vaccines. In addition, scepticism in the general public, often because of misinformation, adds to the problems, with a lack of confidence in vaccines.

These are somewhat addressed with safety profiles of adjuvants being better researched and then put through extended clinical trials to ascertain efficacy without compromising safety. Clear communication, risk versus benefits talk to the public about vaccination programs also helps maintain public trust.

Segmentation Analysis

The market scope is segmented because of by Type, by Route of Administration, by Disease Type, by Application, by Region.

By Type

Based on the Type of the market is segmented into Mineral-based Adjuvants, Emulsion-based Adjuvants, Liposome-based Adjuvants, Saponin-based Adjuvants, Toll-like Receptor (TLR) Agonists, Nanoparticle-based Adjuvants.

Mineral-based adjuvants, mainly aluminium salts, are the most used vaccine adjuvants in the market today because of their long-standing safety record, low cost, and extensive use in paediatric and adult vaccines. They increase the immune response by enhancing antigen uptake and activation of immune cells and, therefore, are critical components in vaccines for diseases such as hepatitis B and diphtheria-tetanus-pertussis (DTP).

Emulsion-based adjuvants include, for instance, MF59 in influenza vaccines that are oil-in-water preparations meant to increase antigen delivery with strong immune responses, especially in elderly populations. Liposome-based adjuvants, lipid-based carriers, improve antigen stability and delivery. Vaccines like Shingrix for shingles activate the immune system over a more prolonged period of time.

Saponin-based adjuvants, such as those from plant sources (for example, QS-21), are known to be strong immunostimulants and are often used in therapeutic cancer vaccines. TLR agonists, for example, the CpG 1018 found in the hepatitis B vaccine Heplisav-B, mimic natural immune signals to increase immunity.

Nanoparticle-based adjuvants represent an innovative category that enables targeted antigen delivery and immune modulation, such as in new mRNA vaccines against COVID-19. Such developments reflect the dynamic market of catering to the diverse needs of vaccines.

By Route of Administration

Based on the Route of Administration of the market is segmented into Injectable Vaccines, Oral Vaccines, Intranasal Vaccines.

The major portion of the vaccine market is injectable because they are effective, and precise delivery into the body does not cause complications. Moreover, injectable vaccines can be used against a range of diseases with intramuscular, subcutaneous, and intradermal routes to provide the appropriate dose and elicit good immune responses. Examples of advanced delivery mechanisms that elicit a strong immune response include the COVID-19 mRNA vaccines, Pfizer-BioNTech and Moderna. Such extensive use of this technique in preventative and therapeutic vaccines makes the injectable vaccines a leader in the market.

Oral vaccines are patient-friendly; they are especially useful for mass immunization in resource-poor settings. They can be used in very low medical staffing because it is easy to administer. They are also useful in inducing mucosal immunity. For example, oral polio vaccines have been instrumental in worldwide efforts to eradicate polio and rely on the safety, effectiveness, and ease of delivery for eradication.

Intranasal vaccines are the emerging segment which targets respiratory pathogens by the induction of immunity directly at mucosal surfaces. They offer the advantage of needle-free administration and, therefore, better compliance by patients, particularly children. One example is FluMist vaccine used for prevention of influenza. Even though they have potential, they are in a developing phase compared to injectable preparations but promise good future applications.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America is expected to be witnessing high growth in the market studied during the forecast period. The key factors driving the growth of the Vaccine Adjuvant Market in the North American region are the presence of key market players, the availability of advanced technology, and the growing government initiatives to launch various awareness campaigns to increase vaccination. For example, in January 2021, the United States Department of Health and Human Services launched the HPV VAX NOW campaign to boost human papillomavirus (HPV) vaccination rates among young adults aged 18-26. In addition, in August 2022, the Government of Canada released the Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022-2023, which updated guidelines for seasonal influenza vaccines usage in Canada. Therefore, an initiative from the government like this is expected to boost the growth of the market. Besides, the market growth is further aided by strategies like product approval, launch, agreements, and developments in the course of the study period. For example, in November 2022, GSK plc said that the US FDA has accepted a Biologics License Application (BLA) and granted priority review to its Respiratory Syncytial Virus (RSV) Older Adult Vaccine Candidate. The US FDA gives a priority review to the applications for vaccines that, if approved, would provide significant enhancements in the safety or the efficacy of the treatment and prevention of serious conditions as compared to standard applications. Therefore, due to the aforementioned factors such as numerous immunization programs, government and non-government initiatives, and increased demand for combined vaccines, the Vaccine Adjuvants Market is anticipated to augment growth over the analysis period. The growth factors of the Vaccine Adjuvants Market are mentioned above.

List of Companies Profiled

• Dynavax Technologies Corporation
• Adjuvatis
• Croda International Plc
• Aurorium
• Novovax Inc.
• InvivoGen
• Air Liquide Group
• GlaxoSmithKline plc.
• Associated British Foods
• Agenus Inc.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Vaccine Adjuvants Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Vaccine Adjuvants Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Vaccine Adjuvants market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Vaccine Adjuvants. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Vaccine Adjuvants companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Vaccine Adjuvants Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Vaccine Adjuvants Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Vaccine Adjuvants Market valued?
• Which region has the largest share in 2024 for the global Vaccine Adjuvants Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Vaccine Adjuvants Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Vaccine Adjuvants Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: